We firmly believe in the fact that the inhalation preparation is and will be the mainstream product in the market.
Our products will be approved in China and EU from year 2021 and on, and with a global sell, we will be a leading company in inhalation products and eyedrops soon.
Congratulations on the Approval of Marketing of Our Salbutamol Sulfate Inhalation Solution with Two Strengths!
On March 24, 2023, we successfully obtained the manufacturing approvals for Salbutamol Sulfate Inhalation Solution with two strengths, with the approval numbers of Guo. Yao. Zhun. Zi. No. H20233355, and Guo. Yao. Zhun. Zi. No. H20233356 respectively, which are deemed to have passed the consistency evaluation.
Salbutamol sulfate is a β2 receptor agonist. It features potent pulmonary function expansion and bronchodilator effect, and is one of the important drugs for the treatment of asthma and chronic obstructive pulmonary disease. With the continuous improvement of inhalation therapy technology, inhalation products are gradually becoming the preferred medication for the treatment of asthma and other diseases. We have been committed to the R&D of drugs in the field of inhalation products. Salbutamol Sulfate Inhalation Solution is our first approved product, signaling the important progress of our R&D achievements in this field.
In the future, we will continue to strengthen our strength, increase our investment in R&D in the field of inhalation products, explore innovative technical means and product applications, and launch more high-quality, innovative and practical drugs, to make new contributions to the cause of human health.
